CHA Mi YAng (KR),ЧА Ми Янг (KR),KANG Seok Dzong (KR),КАНГ Сеок Дзонг (KR),KIM Mi Ra (KR),КИМ Ми Ра (KR),LI Dzu Jeon (KR),ЛИ Дзу Йеон (KR),DZEON Dzi YAng (KR),ДЗЕОН Дзи Янг (KR),DZO Mioung Gi (KR),ДЗО,CHA Mi YAng,ЧА Ми Янг,KANG Seok Dzong,КАНГ Сеок Дзонг,KIM Mi Ra,КИМ Ми Ра,LI Dzu Jeon,ЛИ Дзу Йеон,DZEON Dzi YAng,ДЗЕОН Дзи Янг,DZO Mioung Gi,ДЗО Миоунг Ги,KVAK Eun Dzoo,КВАК Еун Дзоо,LI Kvang Ok,ЛИ Кв
申请号：
RU2014147193/04
公开号：
RU0002598852C2
申请日:
2011.06.20
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
FIELD: chemistry.SUBSTANCE: present invention relates to a novel fused pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof, having Bruton's tyrosine kinase inhibitory activity (ECT). Compounds can be used for preparing a drug for preventing or treating Bruton's tyrosine kinase mediated cancers and tumours, such as leukaemia, lymphoma, B-cell lymphoma, T-cell lymphoma, myeloma, acute lymphoid leukaemia (ALL), chronic lymphoid leukaemia (CLL), etc； inflammatory diseases, such as arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, Still's disease, other arthritic conditions, lupus, etc； autoimmune diseases and immunologically mediated diseases, including Sjorgen's syndrome, autoimmune thyroiditis, hives, multiple sclerosis, sclerodermatitis, rejection of transplanted organs, heterotransplantation, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, associated with diabetes disease, pelvic inflammation, allergic rhinitis, allergic bronchitis, Hodgkin disease, non-Hodgkins lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma, follicular lymphoma, etc. In compounds of formula (I).W is O； X is NH, O, SO or SO2； Y denotes a hydrogen atom, halogen atom, C1-6alkyl or C1-6alkoxy, each of A and B independently denotes a hydrogen atom, halogen atom or di(C1-6alkyl)aminomethyl； Z is selected from a group consisting of formulae Z2, Z4, Z28, Z61, Z100, Z113, Z138, Z164, Z168 and Z189 .EFFECT: treating different diseases.10 cl, 3 dwg, 19 tbl, 237 exНастоящее изобретение относится к новому конденсированному пиримидиновому производному формулы (I) или его фармацевтически приемлемой соли, обладающим ингибирующей активностью в отношении тирозинкиназ Брутона (ВТК). Соединения могут найти применение для получения лекарственного средства для профилактики или лечения опосредованных тирозинкиназой Брутона (ВТК) раков и
